论文部分内容阅读
为探讨P(53)、P(16)基因表达产物与卵巢恶性生殖细胞肿瘤的关系，本文用P(53)基因单克隆抗体和P(16)多克隆抗体采用免疫组化ABC法，对82例卵巢恶性生殖细胞肿瘤和20例正常卵巢组织的P(53)和P(16)基因蛋白表达进行了研究。结果显示；在正常卵巢组织中P(53)蛋白均无表达，P(16)几乎全表达，而在卵巢恶性生殖细胞肿瘤中，P(53)蛋白表达率为24．39％，其阳性定位于胞核；P(16)蛋白表达率为56.10％，其阳性定位在跑浆。两者表达与生殖细胞不同组织学类型无显著相关，P(53)与临床分期、预后有明显关系（P＜0．05、0．01）；P(16)与临床分期无关，但与预后有明显相关（P＞0．05、＜0．01）。提示P(53)和P(16)蛋白表达有可能成为判断卵巢恶性生殖细胞肿瘤预后的指标之一。
In order to investigate the relationship between P (53) and P (16) gene expression and malignant ovarian germ cell tumors, immunohistochemical ABC method using P (53) monoclonal antibody and P (16) polyclonal antibody Cases of ovarian malignant germ cell tumors and 20 cases of normal ovarian tissue P (53) and P (16) gene protein expression were studied. The results showed that there was no expression of P (53) protein in normal ovarian tissues, P (16) almost completely expressed, while in ovarian malignant germ cell tumors, the positive rate of P (53) protein was 24.39% In the nucleus; P (16) protein expression rate of 56.10%, the positive positioning in running pulp. There was no significant correlation between the expression of P (53) and clinical staging and prognosis (P <0.05, 0.01); P (16) had no relationship with clinical stage but with prognosis There was a significant correlation (P> 0.05, <0.01). It is suggested that the expression of P (53) and P (16) proteins may be one of the prognostic indicators of malignant ovarian germ cell tumors.